Skip to content

Study · Systematic review · 2016

6 results

Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.

Twigg SM, Daja MM, O'leary BA, Adena MA

Journal of diabetes4 Apr 2016Cited by 3 (Europe PMC)

PMID26729046 (opens in a new tab)DOI10.1111/1753-0407.12372 (opens in a new tab)PepBankPUB-26729046
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, indirect comparison showed liraglutide 1.2 mg gave a greater HbA1c reduction than twice-daily exenatide (-0.29%).

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found liraglutide 1.2 mg lowered HbA1c more than twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction versus exenatide b.i.d.
    Study

    n: not reported in source

    Comparator
    Exenatide 10 μg twice daily (indirect comparison)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg once dailyAs given in this study (human).

    Measurements

    HbA1c difference
    −0.29%
    liraglutide 1.2 mg vs exenatide b.i.d.

    Source sentences

    Summary
    Compared with exenatide b.i.d., liraglutide 1.2 mg was associated with significantly greater reductions from baseline in HbA1c (-0.29%; 95% confidence interval [CI] -0.53, -0.05)
    1 context sentence
    Summary · context
    Three liraglutide 1.2 mg q.d. (n = 1060) and 10 exenatide b.i.d. (n = 2609) placebo-controlled studies were identified, allowing indirect comparison with placebo as the common arm.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, indirect comparison showed liraglutide 1.2 mg gave a greater fasting plasma glucose reduction than twice-daily exenatide (-0.92 mmol/L).

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found liraglutide 1.2 mg lowered fasting glucose more than twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose reduction versus exenatide b.i.d.
    Study

    n: not reported in source

    Comparator
    Exenatide 10 μg twice daily (indirect comparison)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg once dailyAs given in this study (human).

    Measurements

    FPG difference
    −0.92 mmol/L
    liraglutide 1.2 mg vs exenatide b.i.d.

    Source sentences

    Summary
    Compared with exenatide b.i.d., liraglutide 1.2 mg was associated with significantly greater reductions from baseline in HbA1c (-0.29%; 95% confidence interval [CI] -0.53, -0.05) and fasting plasma glucose (-0.92 mmol/L; 95% CI -1.43, -0.41)
    1 context sentence
    Summary · context
    Three liraglutide 1.2 mg q.d. (n = 1060) and 10 exenatide b.i.d. (n = 2609) placebo-controlled studies were identified, allowing indirect comparison with placebo as the common arm.
  3. 03HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, indirect comparison showed nausea lasted a shorter time with liraglutide 1.2 mg (3 days) than with twice-daily exenatide (14 days).

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found nausea lasted fewer days with liraglutide than with twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseDuration of nausea
    Study

    n: not reported in source

    Comparator
    Exenatide 10 μg twice daily (indirect comparison)
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.2 mg once dailyAs given in this study (human).

    Measurements

    Duration of nausea
    3 days
    liraglutide 1.2 mg
    Duration of nausea
    14 days
    exenatide b.i.d.

    Source sentences

    Summary
    Compared with exenatide b.i.d., liraglutide 1.2 mg was associated with significantly greater reductions from baseline in HbA1c (-0.29%; 95% confidence interval [CI] -0.53, -0.05) and fasting plasma glucose (-0.92 mmol/L; 95% CI -1.43, -0.41), with shorter duration of nausea (3 vs 14 days; P = 0.002
    1 context sentence
    Summary · context
    Three liraglutide 1.2 mg q.d. (n = 1060) and 10 exenatide b.i.d. (n = 2609) placebo-controlled studies were identified, allowing indirect comparison with placebo as the common arm.
  4. 04HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, indirect comparison showed fewer withdrawals with liraglutide 1.2 mg than with twice-daily exenatide (odds ratio 0.34).

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found fewer people stopped liraglutide than twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseWithdrawals
    Study

    n: not reported in source

    Comparator
    Exenatide 10 μg twice daily (indirect comparison)
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.2 mg once dailyAs given in this study (human).

    Measurements

    Withdrawals odds ratio
    0.34 OR
    liraglutide 1.2 mg vs exenatide b.i.d.

    Source sentences

    Summary
    fewer withdrawals (odds ratio 0.34; 95% CI 0.22, 0.52)
    1 context sentence
    Summary · context
    Three liraglutide 1.2 mg q.d. (n = 1060) and 10 exenatide b.i.d. (n = 2609) placebo-controlled studies were identified, allowing indirect comparison with placebo as the common arm.
  5. 05HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, indirect comparison showed similar adverse event incidence (including nausea) between liraglutide 1.2 mg and twice-daily exenatide.

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found similar rates of side effects with liraglutide and twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncidence of adverse events including nausea
    Study

    n: not reported in source

    Comparator
    Exenatide 10 μg twice daily (indirect comparison)
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.2 mg once dailyAs given in this study (human).

    Source sentences

    Summary
    The incidence of adverse events (including nausea) and withdrawals because of adverse events were similar between treatments.
    1 context sentence
    Summary · context
    Three liraglutide 1.2 mg q.d. (n = 1060) and 10 exenatide b.i.d. (n = 2609) placebo-controlled studies were identified, allowing indirect comparison with placebo as the common arm.
  6. 06HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, indirect comparison showed similar withdrawals because of adverse events between liraglutide 1.2 mg and twice-daily exenatide.

    In plain wordsIn adults with type 2 diabetes, an indirect comparison found similar numbers stopped because of side effects with liraglutide and twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    No significant changeWithdrawals because of adverse events
    Study

    n: not reported in source

    Comparator
    Exenatide 10 μg twice daily (indirect comparison)
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.2 mg once dailyAs given in this study (human).

    Source sentences

    Summary
    The incidence of adverse events (including nausea) and withdrawals because of adverse events were similar between treatments.
    1 context sentence
    Summary · context
    Three liraglutide 1.2 mg q.d. (n = 1060) and 10 exenatide b.i.d. (n = 2609) placebo-controlled studies were identified, allowing indirect comparison with placebo as the common arm.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.